Siemens NAEOTOM Alpha Becomes First New Major Technological Improvement for CT Imaging to Receive FDA Clearance in a Decade
By MedImaging International staff writers Posted on 01 Oct 2021 |
Siemens Healthineers’ (Erlangen, Germany) new diagnostic imaging device, called NAEOTOM Alpha, has become the first new major technological improvement for Computed Tomography (CT) imaging to be cleared by the U.S. Food and Drug Administration in nearly a decade.
The device uses the emerging CT technology of photon-counting detectors which can measure each individual X-ray that passes through a patient's body, as opposed to current systems which use detectors that measure the total energy contained in many X-rays at once. By ‘counting’ each individual X-ray photon, more detailed information about the patient can be obtained and used to create images with less information that is not useful in the review and analysis
CT (sometimes called computerized tomography) is a non-invasive medical examination or procedure that uses specialized X-ray equipment to produce cross-sectional images of the body. Each cross-sectional image represents a ‘slice’ of the person being imaged, not unlike the slices in a loaf of bread. These cross-sectional images are used for a variety of diagnostic and therapeutic purposes. CT scans can be performed on every region of the body for a variety of reasons. The CT system then converts these counts or measurements through complex software into the recorded images the health care provider reads and analyzes.
The new Siemens NAEOTOM Alpha diagnostic imaging device is designed to transform the information from X-ray photons that pass through a patient's body, and are received by a detector, into a detailed 3-dimensional image. The images delivered by the system can be used by a trained physician as an aid in diagnosis or can be used by trained staff as an aid in diagnosis, treatment preparation and radiation therapy planning.
“Computed tomography is an important medical imaging tool that can aid in diagnosing disease, trauma or abnormality; planning and guiding interventional or therapeutic procedures; and monitoring the effectiveness of certain therapies,” said Laurel Burk, Ph.D., assistant director of the Diagnostic X-ray Systems Team in the FDA’s Center for Devices and Radiological Health. “Today’s action represents the first major new technology for computed tomography imaging in nearly a decade and underscores the FDA’s efforts to encourage innovation in areas of scientific and diagnostic progress.”
Related Links:
Siemens Healthineers
Latest General/Advanced Imaging News
- PET Scans Reveal Hidden Inflammation in Multiple Sclerosis Patients
- Artificial Intelligence Evaluates Cardiovascular Risk from CT Scans
- New AI Method Captures Uncertainty in Medical Images
- CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
- Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
- CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
- Minimally Invasive Procedure Could Help Patients Avoid Thyroid Surgery
- Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery
- AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning
- Imaging Technology Provides Ground-Breaking New Approach for Diagnosing and Treating Bowel Cancer
- CT Coronary Calcium Scoring Predicts Heart Attacks and Strokes
- AI Model Detects 90% of Lymphatic Cancer Cases from PET and CT Images
- Breakthrough Technology Revolutionizes Breast Imaging
- State-Of-The-Art System Enhances Accuracy of Image-Guided Diagnostic and Interventional Procedures
- Catheter-Based Device with New Cardiovascular Imaging Approach Offers Unprecedented View of Dangerous Plaques
- AI Model Draws Maps to Accurately Identify Tumors and Diseases in Medical Images